Comparing Advanced Accelerator Applications (AAAP) & Its Competitors
Advanced Accelerator Applications (NASDAQ: AAAP) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Advanced Accelerator Applications to similar companies based on the strength of its analyst recommendations, dividends, earnings, valuation, institutional ownership, profitability and risk.
Earnings & Valuation
This table compares Advanced Accelerator Applications and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Advanced Accelerator Applications||$148.26 million||-$20.01 million||-64.17|
|Advanced Accelerator Applications Competitors||$2.40 billion||$905.93 million||3.52|
Advanced Accelerator Applications’ peers have higher revenue and earnings than Advanced Accelerator Applications. Advanced Accelerator Applications is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Advanced Accelerator Applications and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Advanced Accelerator Applications||-33.83%||-16.05%||-11.18%|
|Advanced Accelerator Applications Competitors||-538.85%||-41.85%||-24.81%|
Insider and Institutional Ownership
42.0% of Advanced Accelerator Applications shares are held by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Advanced Accelerator Applications has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Advanced Accelerator Applications’ peers have a beta of 0.81, suggesting that their average stock price is 19% less volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Advanced Accelerator Applications and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Advanced Accelerator Applications||0||1||4||0||2.80|
|Advanced Accelerator Applications Competitors||98||367||965||28||2.63|
Advanced Accelerator Applications presently has a consensus target price of $56.50, suggesting a potential upside of 0.05%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 26.84%. Given Advanced Accelerator Applications’ peers higher possible upside, analysts plainly believe Advanced Accelerator Applications has less favorable growth aspects than its peers.
Advanced Accelerator Applications peers beat Advanced Accelerator Applications on 7 of the 12 factors compared.
Advanced Accelerator Applications Company Profile
Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.
Receive News & Stock Ratings for Advanced Accelerator Applications S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications S.A. and related stocks with our FREE daily email newsletter.